News

Blinatumomab Induces Complete Remissions in Acute Lymphoblastic Leukemia

Publish date: January 23, 2012

 

FROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY

The MT 103-206 trial was supported by Micromet. Dr. Topp and coauthors Dr. Ralf Bargou and Dr. Nicola Goekbuget disclosed consulting for and/or receiving honoraria from the company. Three other coauthors are employees of the company. Dr. Wayne reported no relevant financial disclosures.

Pages

Recommended Reading

FDA Approves Chemotherapeutic Enzyme L-Asparaginase
MDedge Hematology and Oncology
PBSC Transplants from Unrelated Donors Show No Survival Advantage
MDedge Hematology and Oncology
Stem Cell Transplant: Physical, Mental Health Burdens Persist
MDedge Hematology and Oncology
Study Characterizes Spectrum of Somatic Mutations in Chronic Lymphocytic Leukemia
MDedge Hematology and Oncology
Gemtuzumab Extends Survival in Acute Myeloid Leukemia
MDedge Hematology and Oncology
BTK Inhibitor Draws High Response Rate in CLL
MDedge Hematology and Oncology
New Genetic Markers May Tailor Leukemia Treatment
MDedge Hematology and Oncology
Many Elderly AML Patients Not Receiving Chemotherapy
MDedge Hematology and Oncology
Managing Side Effects of Tyrosine Kinase Inhibitor Therapy to Optimize Adherence in Patients with Chronic Myeloid Leukemia: The Role of the Midlevel Practitioner
MDedge Hematology and Oncology
The impact of myelodysplastic syndromes on quality of life: lessons learned from 70 voices
MDedge Hematology and Oncology